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Abstract
Purpose: Hormone receptor–positive (HRþ) breast cancer is
clinically and biologically heterogeneous, and subgroups with
different prognostic and treatment sensitivities need to be
identified.
Experimental Design: Research-based PAM50 subtyping and
expression of additional genes was performed on 63 patients with
HRþ/HER2 disease randomly assigned to neoadjuvant multia-
gent chemotherapy versus endocrine therapy in a phase II trial.
The biology associatedwith treatment responsewas used to derive
a PAM50-based chemoendocrine score (CES). CES's predictive
ability was evaluated in 4 independent neoadjuvant data sets
(n¼ 675) and 4 adjuvant data sets (n¼ 1,505). The association of
CES, intrinsic biology, and PAM50 risk of relapse (ROR) was
explored across 6,007 tumors.
Results:Most genes associated with endocrine sensitivity were
also found associated with chemotherapy resistance. In the che-
motherapy test/validation data sets, CES was independently asso-
ciatedwithpathologic complete response (pCR), evenafter adjust-
ing for intrinsic subtype. pCR rates of the CES endocrine–sensitive
(CES-E), uncertain (CES-U), and chemotherapy-sensitive (CES-C)
groups in both data sets combined were 25%, 11%, and 2%,
respectively. In the endocrine test/validation data sets, CES was
independently associated with response. Compared with ROR,
>90%of ROR-low and ROR-high tumors were identified as CES-E
and CES-C, respectively; however, each CES group represented
>25%of ROR-intermediate disease. In terms of survival outcome,
CES-C was associated with poor relapse-free survival in patients
with ROR-intermediate disease treatedwith either adjuvant endo-
crine therapy only or no adjuvant systemic therapy, but not in
patients treated with (neo)adjuvant chemotherapy.
Conclusions:CES is a genomic signature capable of estimating
chemoendocrine sensitivity inHRþ breast cancer beyond intrinsic
subtype and risk of relapse. Clin Cancer Res; 23(12); 3035–44. 2016
AACR.
Introduction
Approximately 70% of invasive breast cancers at diagnosis
are hormone receptor–positive and HER2-negative (HRþ/
HER2; ref. 1, 2). However, HRþ/HER2 disease is clinically
and biologically heterogeneous and further subclassifica-
tions are needed to better tailor current and future treat-
ments (3–5).
Over the last decade, molecular characterization studies have
identified and extensively investigated the two main molecular
subtypes within HRþ/HER2 disease (i.e., Luminal A and B;
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refs. 1, 2, 6). Luminal A tumors have an improved prognosis at
5- and 10-year follow-up compared with Luminal B tumors
irrespective of classical clinical–pathologic variables (e.g.,
tumor size and nodal status) and (neo)adjuvant treatment
(i.e., endocrine and chemotherapy; refs. 1, 2, 7, 8). In terms
of treatment sensitivity, Luminal A tumors achieve significant
lower rates of pathologic complete response (pCR) than Lumi-
nal B tumors following neoadjuvant multiagent chemotherapy
(9–12). However, less clear is the difference in endocrine
sensitivity between the two luminal subtypes (13, 14).
Today, adjuvant endocrine therapy for 5 to 10 years is
recommended for all patients with HRþ/HER2 early breast
cancer, whereas chemotherapy is recommended for patients
with intermediate- and high-risk tumors (15). However, the
relationship between therapy and risk warrants further
study considering that risk is associated with both factors
related to tumor biology and clinical–pathologic features
such as tumor size and nodal status, whereas therapy respon-
siveness is generally considered to be independent of clinical–
pathologic factors.
Materials and Methods
GEICAM/2006-03 clinical trial
Pretreatment core biopsy samples frompatients recruited in the
luminal cohort of the GEICAM/2006-03 phase II neoadjuvant
clinical trial were evaluated (16). In this study, 95 patients with
estrogen receptor (ER)–positive (Allred 3–8), progesterone recep-
tor (PR)–positive (Allred 3–8), HER2 (according to the ASCO/
CAP guidelines; ref. 17), and cytokeratin 8/18-positive breast
cancer were randomly assigned to receive 24 weeks of neoadju-
vant chemotherapy or endocrine therapy. Chemotherapy con-
sisted of epirubicin combined with cyclophosphamide for 4
cycles followed by docetaxel for 4 cycles. Endocrine therapy
consisted of oral exemestane. Premenopausal patients received
goserelin for 6 doses.
GEICAM 2006-03 pathologic response endpoint
The 5-point scale Miller and Payne histologic grading system
(18)was used tomeasure tumor response. In this study, theMiller
and Payne scale was reduced to a 3-point scale in order to have a
fair number of cases in each category and arm:no response (grades
1 and 2), intermediate response (grade 3), and high response
(grades 4 and 5).
GEICAM 2006-03 gene expression analysis
Sixty-three of 95pretreatment tumor sampleswere available for
gene expression analyses. Total RNA was purified to measure the
expression of 543 breast cancer–related genes, 5 housekeeping
genes and 14 negative and positive controls using the nCounter
platform (Nanostring Technologies; ref. 19). Raw gene expression
can be found in Supplementary Material.
Independent/testing data sets
Gene expression and response data were evaluated from 4
independent neoadjuvant data sets (Supplementary Material;
refs. 14, 20–24). Gene expression and survival data were evalu-
ated from 4 independent data sets of patients with early breast
cancer (Supplementary Material; refs. 2, 20, 25, 26).
Intrinsic subtype assignment
All tumors were assigned to an intrinsic molecular subtype of
breast cancer (Luminal A, Luminal B, HER2-enriched, Basal-like)
and the normal-like group using the research-based PAM50
subtype predictor (27, 28), except for the Malaga cohort where
the PAM50 standardized and commercial nCounter-based assay
was used. Before subtyping, each individual dataset was normal-
ized accordingly as previously reported (29), except for the
Malaga cohort that was normalized by Nanostring according to
their algorithm. Of note, the Edinburghmicroarray-based dataset
is composed of ERþ samples-only and proper centering for
intrinsic subtyping calling was not possible (30). In this dataset,
CES was evaluated as a continuous variable since it is not affected
by centering.
Combined cohort of primary breast cancer
To evaluate the relationship between PAM50 subtype calls,
prognosis (ROR-P) and CES, we combined PAM50 data from 7
independent andpreviously reported cohorts (1, 2, 11, 20, 31–33)
representing a total of 6,007 primary tumor samples. CES was
evaluated in each individual cohort, and a combined matrix was
created (Supplementary Material).
Statistical analysis
Biologic analysis of gene lists was performed with DAVID
6.7 annotation tool (34) using the 543-gene list as back-
ground. The association between the expression of each gene
and Miller–Payne response (3 categories) was assessed by a
quantitative Significance Analysis of Microarrays (SAM;
ref. 35). In both testing data sets, association between each
variable and pCR or clinical/radiological response was
assessed by univariate and multivariable logistic regression
analyses. The predictive performance of CES was evaluated
using receiver operating characteristic (ROC) curve analysis.
Estimates of survival were from the Kaplan–Meier curves and
tests of differences by the log-rank test. Univariate and mul-
tivariable Cox models were used to test the independent
prognostic significance of each variable. Reported P values are
two sided.
Translational Relevance
Hormone receptor–positive (HRþ) breast cancer is clinically
and biologically heterogeneous, and subgroups with different
prognostic and treatment sensitivities need to be identified.
Here, we present the development and clinical validation
across multiple studies of a gene expression–based predictor,
based on the well-known PAM50 assay, which is associated
with chemotherapy and endocrine therapy response in early
breast cancer beyond PAM50 risk of relapse (ROR) and intrin-
sic subtypes. The potential clinical utility of this PAM50-based
chemoendocrine score (CES) predictormight be in the PAM50
ROR intermediate, where the proportion of each CES group
(endocrine-sensitive, intermediate, and chemosensitive) is
more than 25%. This is important as we await the results of
large adjuvant clinical trials, such as TailorX or RxPonder, that
have randomly assigned patients with intermediate risk to
adjuvant chemotherapy or not.
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Results
GEICAM 2006-03 dataset
Sixty-three pre- and postmenopausal patientswere evaluated in
this study (Table 1). Most patients presented ductal carcinomas
(83%), tumor sizes of 2 to 5 cm (76%), histologic grade 3 tumors
(59%), clinical node-negative disease (54%), and luminal disease
by PAM50 (84%).
Following chemotherapy, Luminal B tumors showed higher
Miller–Payne response than Luminal A disease (mean 2.0 vs. 1.4,
P ¼ 0.048). However, no difference in response between the
two luminal subtypes was observed following endocrine
therapy (P ¼ 0.407). In addition, no statistical significant inter-
action (P¼ 0.429) between subtype and treatment (endocrine vs.
chemotherapy) for tumor response was observed. Interestingly,
the only patient who achieved a pCR (i.e., Miller–Payne grade 5)
had a Basal-like tumor and was contained within the chemother-
apy arm.
Gene expression association with treatment sensitivity
To understand the biology associated with either chemother-
apy or endocrine sensitivity within HRþ/HER2 disease, we
explored the association between the expression of 543 breast
cancer–related genes and Miller–Payne response in each treat-
ment arm. High expression of 70 (12.9%) and 17 (3.1%) genes
was found significantly associated (P < 0.05 uncorrected for
multiple comparisons) with response after endocrine therapy
and chemotherapy, respectively. The gene list associated with
endocrine therapy response was enriched for the following bio-
logical processes (Supplementary Material): vasculature develop-
ment (e.g., AKT1 and catenin beta 1), tube development (e.g.,
FOXA1 and gremlin 1), and cell growth (e.g., androgen receptor
and fibroblast growth factor receptor 1). On the other hand, the
gene list associated with chemotherapy response was enriched for
cell cycle (e.g., EXO1 and MKI67) and extracellular matrix (e.g.,
netrin 4 and thrombospondin 1).
We then evaluated the interaction between the expressions of
each individual gene with response to therapy (endocrine vs.
chemotherapy). Interestingly, 41 of the 70 genes associated with
response to endocrine therapy, and 8 of 17 genes associated with
chemotherapy response, showed a significant interaction with
treatment (P < 0.05 uncorrected formultiple comparisons). Thus,
the biological factors associated with endocrine sensitivity
seemed to be associated, at the same time, with chemotherapy
resistance, and vice versa. Indeed, an overall inverse pattern was
observed between expression of most genes and response to
treatment (Fig. 1A).
To further understand the biological factors associated with
treatment response, we evaluated the mean expression of genes
associated with high endocrine but low chemotherapy sensitivity,
or low endocrine but high chemotherapy sensitivity, across 1,034
primary tumors representing all intrinsic molecular subtypes of
breast cancer (Fig. 1B). The results revealed that the biology
associated with chemoendocrine sensitivity is mostly driven by
the Luminal A (i.e., high endocrine but low chemotherapy sen-
sitive) versus Basal-like biology (i.e., low endocrine but high
chemotherapy sensitive).
Development of a PAM50-based CES
Our previous results suggested that capturing the relative
differences in the Luminal A versus Basal-like biology within
HRþ/HER2 could help better predict endocrine and chemother-
apy sensitivity. To capture this biological state in each tumor, we
obtained, from the PAM50 classification algorithm, the correla-
tion coefficients (CC) of each sample to the PAM50 Luminal A
and Basal-like subtype centroids, and then subtracted the 2 values
to create the chemoendocrine score (CES¼CC to Luminal A –CC
to Basal-like). Thus, samples with a positive score were identified
as being more endocrine sensitive than chemotherapy sensitive,
whereas samples with a negative score were identified as being
more chemotherapy sensitive (CES-C) than endocrine sensitive
(CES-E; Fig. 1C). From GEICAM 2006-03 samples, cutoffs based
on tertile groups were determined [CES-E vs. CES uncertain
(CES-U) group, cutoff ¼ 0.70; CES-U vs. CES-C group, cutoff ¼
0.30]. The interaction of the CES score (as a continuous variable)
with treatment in the GEICAM 2006-03 trial provides some
evidence of association (P ¼ 0.059).
MDACC-based dataset
We evaluated a combined dataset of 272 patients with
HRþ/HER2 disease treated with anthracycline/taxane-based
neoadjuvant chemotherapy across several neoadjuvant trials
(Fig. 1D and Table 2). In this dataset, 51.5%, 25.8%, and 22.7%
of the sampleswere identifiedasCES-E, -U, and -C, respectively. The
rates of pCR across the CES-E, -U, and -C groups were 2.4%, 9.0%,
and 23.7%, respectively (P < 0.0001), andwere found to be similar
even if non-luminal tumors were removed (2.2%, 8.8%, and
25.0%). The neoadjuvant chemotherapy predictive ability of CES
was independent of clinical–pathologic variables and intrinsic
subtype (Table 3; Supplementary Table S1). Similar results were
Table 1. Clinical–pathologic characteristics and subtype distribution in the
GEICAM 2006-03 study
CT (%) ET (%) P
Number 32 (—) 31 (—) —
Age (mean) 53.7 (—) 52.3 (—) 0.596
Menopausal status
Premenopausal 14 (44%) 14 (45%) 1.000
Postmenopausal 18 (56%) 17 (55%)
Tumor stage
T1 1 (3%) 2 (6%) 0.420
T2 23 (72%) 25 (81%)
T3 8 (25%) 4 (13%)
Mean tumor size (cm) 4.2 3.8 0.278
Node
N0 15 (47%) 19 (61%) 0.501
N1 16 (50%) 11 (35%)
N2 1 (3%) 1 (3%)
Grade
G1 0 (0%) 0 (0%)
G2 8 (25%) 6 (19%) 0.862
G3 18 (56%) 19 (61%)
G4 6 (19%) 6 (19%)
Histologic type
Ductal 26 (81%) 26 (84%) 1.000
Lobular 2 (6%) 2 (6%)
Others 4 (13%) 3 (10%)
Ki-67 IHC (mean) 31.1 33.5 0.720
Miller–Payne response (mean) 2.6 2.2 0.124
PAM50
Luminal A 16 (50%) 13 (42%) 0.564
Luminal B 11 (34%) 13 (42%)
HER2-E 0 (0%) 1 (3%)
Basal-like 2 (6%) 0 (0%)
Normal-like 3 (9%) 4 (13%)
Abbreviations: CT, chemotherapy arm; ET, endocrine therapy arm.
PAM50-Based Chemoendocrine Score
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obtained when residual cancer burden (RCB) was used as the
endpoint (Supplementary Tables S2 and S3).
Six gene expression-based signatures (i.e., PAM50 proliferation
score, ROR-P, genomic grade index, SET index, chemopredictor,
DLDA30, and RCB predictor) have been previously reported in
this dataset (20). In addition, we applied a microarray-based
version of OncotypeDX Recurrence Score (36, 37). Here, we
evaluated the performance of CES to predict pCR within
HRþ/HER2 disease compared with these 7 gene signatures.
Interestingly, CES provided the highest aROC (Supplementary
Tables S4–S12) either as a continuous variable (aROC¼ 0.770)
or as group categories (aROC ¼ 0.765). The second most
predictive signature was the RCB predictor (aROC ¼ 0.740).
Of note, the RCB predictor was trained using 165 of 272
(60.7%) HRþ/HER2 samples from this dataset (i.e., the train-
ing dataset). When these training samples were removed, CES
showed a higher performance either as a continuous variable
(aROC ¼ 0.805) or as group categories (aROC ¼ 0.786) than
the RCB predictor (aROC ¼ 0.640).
Malaga-based dataset
We evaluated a dataset of 180 patients with HRþ/HER2
disease treatedwith anthracycline/taxane-based neoadjuvant che-
motherapy (Table 2). In this dataset, 46.1%, 16.1%, and 37.8%of
the samples were identified as CES-E, -U, and -C, respectively. The
pCR and RCB 0/1 rates across the CES-E, -U, and -C groups were
2.4%/9.6%, 3.4%/17.2%, and 13.2%/30.9%, respectively (P ¼
0.022 and 0.004).
To test the ability of CES to predict chemotherapy response
independently of known clinical–pathologic variables and
intrinsic subtype, we performed a multivariable logistic regres-
sion analysis using RCB (0/1 vs. 2/3) as the endpoint since only
12 samples achieved a RCB 0 (i.e., pCR) in this dataset. The
results revealed that CES provided independent predictive infor-
mation beyond intrinsic subtype (Table 4), Ki-67 by IHC (Sup-
plementary Table S13) and PAM50 ROR score (Supplementary
Table S14). The aROC of CES for predicting RCB 0/1 was 0.746.
Finally, we observed a significant association between CES and
Miller–Payne response data (Supplementary Fig. S1).
Marsden-based dataset: CES and endocrine sensitivity
We evaluated a dataset of 103 postmenopausal patients with
HRþ disease treated with anastrozole for 16 weeks in the neoadju-
vant setting (Table 2). In this dataset, 23.5%, 34.3%, and 42.2% of
samples were identified as CES-E, -U, and -C, respectively. Clinical
tumor response (complete and partial response versus stable and
progressive disease) was used as the endpoint. No pCR was
observed in this dataset. The rates of clinical tumor response across
the CES-E, -U, and -C groups were 75.0%, 48.6%, and 44.2%,
respectively (P ¼ 0.043). CES was found to be the only variable
significantly associated with response (Supplementary Table S15),
independently of HER2 status (Supplementary Tables S15–S16).
Edinburgh-based dataset: CES and endocrine sensitivity
We evaluated a dataset of 120 postmenopausal patients with
HRþ disease treated with letrozole for at least 12 weeks in the
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Figure 1.
Gene expression association with either
chemotherapy or endocrine therapy
sensitivity. A, Association between the
expression of each individual gene
(n ¼ 542) and Miller–Payne response in
each arm of the GEICAM 2006-03 trial.
Selected top genes whose expression is
found significantly associated with
response are shown on the right. B, Mean
expression of the top 50genes associated
with endocrine sensitivity (top) and
chemotherapy sensitivity (bottom) in the
GEICAM 2006-03 trial across the
intrinsic subtypes of breast cancer. The
RNAseq-based gene expression data
have been obtained from The Cancer
Genome Atlas breast cancer project data
portal (https://gdc.cancer.gov/). C,
Significance and scoring
of the CES. D, Association of CES (as a
continuous variable) with chemotherapy
or endocrine therapy response in the 4
validation data sets.
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neoadjuvant setting (Supplementary Fig. S2A). Two patients of
120 achieved a complete response. Similar to previous results,
CES as a continuous variable was found to be the only variable
significantly associated with a 70% reduction in tumor volume
by 90 days (Supplementary Fig. S2B), even within HER2-negative
disease (Supplementary Fig. S2C).
Table 2. Clinical–pathologic characteristics and subtype distribution of the 4 testing sets
MDACC Malaga Marsden Edinburgh
N (%) N (%) N (%) N (%)
Treatment CT CT ET ET
N 272 180 103 120
HER2 statusa
HER2-negative 272 (100%) 180 (100%) 89 (86%) 31 (69%)
HER2-positive 0 (0%) 0 (0%) 14 (14%) 14 (31%)
Age (mean) 50.1 50.0 53.7 76.1
Menopausal status
Premenopausal NA 108 (60%) 0 (0%) 0 (0%)
Postmenopausal NA 72 (40%) 103 (100%) 120 (100%)
Tumor stage
T0–T1 19 (7%) 18 (10%) 60 (58%) 10 (9%)
T2 142 (52%) 115 (67%) 42 (36%)
T3–T4 111 (41%) 39 (23%) 43 (42%) 63 (55%)
Node
N0 96 (35%) 67 (37%) 61 (59%) 86 (72%)
N1 133 (49%) 61 (34%) 39 (38%) 34 (28%)
N2–N3 43 (16%) 52 (29%) 3 (3%)
Grade
G1 28 (11%) 27 (16%) 15 (15%) 13 (11%)
G2 136 (53%) 96 (57%) 63 (62%) 82 (68%)
G3 91 (36%) 46 (27%) 24 (23%) 25 (21%)
ET response rateb NA NA 53% 72%
CT response rate
pCR breast/axilla 8.8% 6.7% NA NA
PAM50
Luminal A 141 (52%) 54 (30%) 37 (36%) —
Luminal B 102 (38%) 105 (58%) 20 (19%) —
HER2-E 6 (2%) 7 (4%) 12 (12%) —
Basal-like 7 (2%) 14 (8%) 4 (4%) —
Normal-like 16 (6%) — 30 (29%) —
Abbreviations: CT, chemotherapy, ET, endocrine therapy.
aEdinburgh dataset has 75 patients without clinical HER2 status.
bThe definition of ET response is different in theMarsden and Edinburgh data sets. Clinical tumor response (complete and partial response vs. stable and progressive
disease) was used as the endpoint in the Marsden dataset. Response was evaluated by imaging ultrasound in the Edinburgh dataset. Clinical tumor response was
defined as tumor volume shrinkage of at least 70% by 90 days of treatment.
Table 3. CES association with chemotherapy sensitivity in the MDACC-based dataset
Univariate analysis Multivariable analysis
Signatures N pCR rate OR Lower 95% Upper 95% P OR Lower 95% Upper 95% P
Age (cont. variable) — — 1.0 0.93 1.02 0.251 1.0 0.92 1.02 0.205
Tumor size
T0–T2 153 8% 1.0 — — — 1.0 — — —
T3–T4 107 9% 1.1 0.47 2.63 0.813 0.6 0.22 1.70 0.341
Nodal status
N0 96 7% 1.0 — — — 1.0 — — —
N1 125 9% 1.2 0.46 3.29 0.685 0.9 0.30 2.78 0.882
N2–3 39 13% 1.9 0.56 6.29 0.312 1.0 0.24 4.51 0.965
Grade
1 26 4% 1.0 — — — 1.0 — — —
2 130 4% 1.0 0.11 8.93 1.000 0.7 0.07 6.88 0.753
3 89 17% 5.1 0.64 40.34 0.125 1.8 0.18 18.42 0.608
PAM50
Luminal A 134 3% 1.0 — — — 1.0 — — —
Luminal B 99 15% 5.8 1.86 18.08 0.002 1.2 0.25 6.28 0.792
HER2-E 6 0% 0.0 — — 0.989 0.0 — — 0.991
Basal-like 7 29% 13.0 1.91 88.50 0.009 0.4 0.02 9.97 0.586
Normal-like 14 14% 5.4 0.90 32.69 0.065 1.7 0.23 12.75 0.602
CES
CES-E 134 2% 1.0 — — — — — — —
CES-U 67 9% 4.3 1.04 17.75 0.044 — — — —
CES-C 59 24% 13.6 3.73 49.46 <0.001 — — — —
CES (cont. variable) — — 0.2 0.08 0.40 <0.001 0.2 0.03 0.77 0.022
PAM50-Based Chemoendocrine Score
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Prognosis, intrinsic subtype, and chemoendocrine sensitivity
To better understand the relationship between prognosis,
intrinsic biology, and chemoendocrine sensitivity, we pulled
together PAM50 data from many different data sets for a total
of 6,007 primary breast cancers representing all subtypes (Fig. 2).
The results revealed that in the ROR-low group, 94.9% of cases
were identified asCES-E and100%were of the Luminal A subtype.
In the ROR-high, 92.1% of the samples were identified as CES-C;
non-luminal and Luminal B subtypes represented 64.3% and
35.7% of the ROR-high/CES-C cases, respectively.
In the ROR-intermediate group, high heterogeneity was
observed. In terms of intrinsic biology, Luminal A, Luminal
B, and non-Luminal subtypes represented 44.4%, 31.5%, and
24.1%, respectively. In terms of chemo/endocrine-sensitivity,
CES-E, CES-U, and CES-C represented 40.6%, 30.3%, and
29.1%, respectively. As expected, the vast majority of ROR-
intermediate/CES-E samples (77.3%) were of the Luminal A
subtype.
Survival outcome of CES within HRþ/ROR-intermediate
disease
To continue exploring the value of CES within HRþ/ROR-
intermediate disease, we evaluated the association of CES with
survival outcome in HRþ/ROR-intermediate early breast cancer
in 4 independent data sets of patients treated with no adjuvant
systemic therapy (n¼ 189), adjuvant tamoxifen-only (n ¼ 846)
or adjuvant chemotherapy and endocrine therapy (n ¼ 322 and
n ¼ 148).
In patientswith node-negative disease treatedwithout adjuvant
systemic therapy, CES (as a continuous variable or as group
categories) was found significantly associated with distant
relapse-free survival (Fig. 3A). The hazard ratio between the
Table 4. CES association with chemotherapy sensitivity in the Malaga dataset
Univariate analysis Multivariable analysis
Signatures N RCB0/1 rate OR Lower 95% Upper 95% P OR Lower 95% Upper 95% P
Age (cont. variable) — — 1.0 0.95 1.02 0.331 1.0 0.96 1.07 0.599
Tumor size
T0–T2 133 22% 1.0 — — — 1.0 — — —
T3–T4 39 10% 0.4 0.13 1.25 0.116 0.4 0.09 1.90 0.260
Grade
1 27 7% 1.0 — — — 1.0 — — —
2 96 16% 2.3 0.50 10.82 0.286 1.6 0.26 9.31 0.625
3 46 35% 6.7 1.40 31.82 0.017 3.0 0.40 23.34 0.283
PAM50
Luminal A 54 9% 1.0 — — — 1.0 — — —
Luminal B 105 20% 2.4 0.87 6.91 0.090 0.9 0.19 4.34 0.905
HER2-E 7 14% 1.6 0.16 16.43 0.677 0.1 0.00 3.19 0.188
Basal-like 14 50% 9.8 2.43 39.51 0.001 0.1 0.00 3.40 0.214
CES
CES-E 83 10% 1.0 — — — — — — —
CES-U 29 17% 2.0 0.58 6.54 0.277 — — — —
CES-C 68 31% 4.2 1.72 10.22 0.002 — — — —
CES (cont. variable) — — 0.2 0.09 0.44 <0.001 0.2 0.07 0.76 0.016
100806040200
2.0
1.0
0
–1.0
–2.0
Luminal B
Luminal A
HER2-E
Basal-like
Subtypes
C
ES
 S
C
O
R
E
PAM50 ROR
ROR-LOW ROR-INTERM ROR-HIGH
C
ES
-C
C
ES
-E
Pa
tie
nt
s,
 n
BA
0
400
800
1,200
1,600
2,000
C
ES
-C
C
ES
-U
C
ES
-E
C
ES
-C
C
ES
-U
C
ES
-E
C
ES
-C
C
ES
-U
C
ES
-E
ROR-LOW ROR-INTERM ROR-HIGH
Figure 2.
Prognosis (PAM50 ROR), intrinsic subtype, and CES in 6,007 primary breast cancers. A, A scatter plot of CES score and ROR score, colored by subtype, is
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CES-C group versus the CES-E group was 2.68 (95% confidence
interval, 0.163–0.858). Similar results were obtained in the data-
set where patients were treated with adjuvant tamoxifen-only
(Fig. 3B). However, CES (as a continuous variable or as group
categories) was not found significantly associated with survival
outcome in 2 independent cohorts of patients treated with (neo)
adjuvant chemotherapy and endocrine therapy (Fig. 3C and D).
Discussion
Our results are the first to confirm, in a randomized setting,
an inverse relationship of endocrine and chemotherapy sensi-
tivity in ERþ breast cancer. Previous evidence has suggested an
inverse relationship of proliferation- and ER-related biological
processes regarding endocrine and chemotherapy sensitivity of
ERþ breast cancer. For example, two independent studies
showed an inverse correlation between a 200-gene ER reporter
score, or between TAU expression, an ER-related gene, and
endocrine sensitivity and chemosensitivity (38, 39). In addi-
tion, high recurrence score measured by Oncotype DX (Geno-
mic Health, Inc.) predicted little or no benefit from adjuvant
tamoxifen therapy in the NSABP-B14 trial, but at the same time
also predicted substantial benefit from adjuvant CMF chemo-
therapy in the NSABP-B20 trial (40, 41). These results fit with
our results showing that virtually all patients with ROR-high
disease are identified as CES-C; however, our data also highlight
that within ROR-high/CES-C disease not all ERþ/HER2 sam-
ples are luminal (i.e., Luminal A or B) since non-luminal disease
(i.e., Basal-like and HER2-enriched) can also be identified.
According to our results (Fig. 2), the chemotherapy benefit of
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Figure 3.
Survival outcomes in HRþ early breast cancer with ROR-intermediate disease. A, Node-negative disease treated without adjuvant systemic therapy.
B, Node-negative and node-positive disease treated with adjuvant tamoxifen only. C, Node-positive disease treated with adjuvant chemotherapy and
endocrine therapy in the GEICAM/9906 clinical trial. D, Node-negative and node-positive disease treated with neoadjuvant chemotherapy and adjuvant
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ROR-high/non-luminal tumors within HRþ/HER2 disease is
likely even greater than ROR-high/Luminal B tumors.
Our results also suggest that amain driver of endocrine therapy
sensitivity and chemotherapy sensitivity within ERþ/HER2 dis-
ease is the Basal-like versus Luminal A intrinsic biology. To
capture both biological states in each individual sample, we
calculated the correlation coefficients of each sample to both
PAM50 centroids (i.e., Luminal A and Basal-like) and then sub-
tracted both coefficients. Thus, instead of choosing a gene signa-
ture (e.g., a proliferation-based signature) of the many signatures
that can discriminate between both subtypes in one way or
another, we decided to incorporate into a score the Basal-like
versus Luminal A intrinsic state of each tumor as identified by the
PAM50 subtype predictor. Of note, the PAM50 genes were orig-
inally selected for their ability to capture the intrinsic biology
displayed by 1,900 genes (i.e., the so-called intrinsic gene list). In
fact, in the TCGA, intrinsic subtype defined by PAM50 captured
the vast majority of the biological diversity displayed by most
molecular data types analyzed (1).
From a clinical perspective, our results support current breast
cancer guidelines for the systemic treatment of early HRþ/HER2
breast cancer. On the one hand, patients with a low-ROR score
and a low tumor burden (i.e., <10% risk of distant relapse at 10
years) are recommended to be treated with endocrine therapy-
only (42). Indeed, our results suggest that these patients have
tumors that are highly endocrine sensitive and have low chemo-
therapy sensitivity. On the other hand, patients with high-risk
HRþ/HER2 disease are recommended to be treated with
endocrine therapy and chemotherapy. According to our anal-
ysis, this group is the one with high chemotherapy benefit and
low endocrine benefit. Regarding endocrine therapy in this
group, the main issue is that we do not have survival data
suggesting that CES-C tumors do not benefit at all from endo-
crine therapy. Therefore, withdrawal of a potentially efficacious
treatment strategy such as endocrine therapy in a patient with
an ERþ tumor (as defined by the ASCO/CAP guidelines) that is
identified as CES-C or ROR-high should not be recommended
today, although in patients whose tumors contain low levels of
ER (1% to 10%), ASCO/CAP recommend to discuss the pros
and cons of endocrine therapy. A large randomized adjuvant
trial involving thousands of patients to answer this particular
question is unlikely to happen.
Although the clinical implications of CES in low- and high-risk
HRþ/HER2 disease are minimal, the observation that interme-
diate-risk HRþ/HER2 disease, which represents 30% of newly
diagnosed breast cancer, is biologically heterogeneous with a
range of chemotherapy sensitivities might have implications for
the interpretation of two ongoing prospective clinical trials. In the
TailorX phase III trial, 4,500 patients with HRþ/HER2 node-
negative early breast cancer with intermediate RS have been
randomly assigned to adjuvant chemotherapy or no chemother-
apy. According to our analysis, this intermediate group might be
composed of at least 3 groups with different chemotherapy
sensitivities. Of note, the CES-U group seems to be a genuine
gray area where decisions regarding the need of chemotherapy
might be difficult. A similar situation might occur in the RxPON-
DER phase III clinical trial where patients with HRþ/HER2 early
breast cancer, and 1-3-positive lymph nodes, with low/interme-
diate risk are being randomly assigned to adjuvant chemotherapy
or not. A potential explanation is that OncotypeDX RS, as well as
other prognostic gene expression-based tests, such as PAM50ROR
or MammaPrint (43), have been specifically designed or trained
to predict outcome and not intrinsic tumor biology or treatment
sensitivity. Although a strong negative correlation is observed
between ROR (risk) and CES (drug sensitivity), there are sub-
stantial differences between them at the individual level (40%
discordance).
There are several caveats to our study. First, this is a retrospective
study involving heterogeneous patient populations and the
results need to be confirmed in a prospective clinical trial(s).
Second, although the data presented here validate CES from a
clinical perspective, further analytical validation will be needed,
since in most data sets, except the Malaga set, the research-based
version of PAM50 was used. However, the fact that CES (as a
continuous variable and the 2 cutoff points) predicted pCR in the
Malaga set suggests that analytical validation of this biomarker is
feasible. Third, we did not evaluate the association of CES with
survival data from a randomized clinical trial of adjuvant che-
motherapy versus no adjuvant chemotherapy, or adjuvant endo-
crine therapy versus no adjuvant endocrine therapy. Thus, the
predictive value of these signatures was evaluated only in the
neoadjuvant setting where different tumor response endpoints
were evaluated, most of which have been associated with patient
survival (18, 44). Fourth, some of the signatures evaluated in the
MDACC-based dataset, such as OncotypeDX recurrence score or
genomic grade index, were derived from microarray-based data
and thus are not the commercially available versions. Fifth, we
were not able to demonstrate a consistent association of CES with
endocrine response in HRþ disease after excluding the HER2-
positive cases. In the Edinburgh dataset, HER2 status was not
available for all patients. Although we derived an ERBB2 expres-
sion-based surrogate definition of HER2 status and showed that
CES is independently associated with response, this was not
prespecified and does not meet REMARK guidelines. In addition,
the association of CES with endocrine response did not reach
statistical significance (P ¼ 0.09) in patients with HRþ/HER2
disease in the Marsden dataset. Finally, patients from each of the
data sets received different anthracycline/taxane-based chemo-
therapy regimens, schedules, and doses, and thus the ability of the
signatures to predict response to particular chemotherapeutics or
treatment regimens could not be tested.
Another important consideration of our study is thatwedid not
attempt to identify anoptimal cutoff(s) forCES but rather focused
on the association of the continuous expression of CES with each
endpoint. Themain reason is that different gene expression-based
platforms and protocols were used in each cohort and, thus,
standardization of a biomarker cutoff point would have been
difficult to achieve andmost likely unreliable. In any case, the fact
that all four testing sets gave very similar associations, and were
found independently of the platform/protocol used, argues in
favor of a robust finding.
To conclude, CES is a single genomic signature capable of
measuring chemoendocrine sensitivity in HRþ/HER2 breast
cancer beyond intrinsic subtype, other genomic signatures, and
the standard pathology variables. CES could be of particular
clinical value in patients with HRþ/HER2 intermediate-risk
disease where the benefit of adjuvant multiagent chemotherapy
is unclear.
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